| Diverse somatic mutation patterns and pathway alterations in human cancers Z Kan, BS Jaiswal, J Stinson, V Janakiraman, D Bhatt, HM Stern, P Yue, ... Nature 466 (7308), 869-873, 2010 | 1195 | 2010 |
| Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival M Schwickart, XD Huang, JR Lill, J Liu, R Ferrando, DM French, ... Nature 463 (7277), 103-107, 2010 | 720 | 2010 |
| The mutation spectrum revealed by paired genome sequences from a lung cancer patient W Lee, Z Jiang, J Liu, PM Haverty, Y Guan, J Stinson, P Yue, Y Zhang, ... Nature 465 (7297), 473-477, 2010 | 630 | 2010 |
| SNPs3D: candidate gene and SNP selection for association studies P Yue, E Melamud, J Moult BMC bioinformatics 7, 1-15, 2006 | 559 | 2006 |
| Loss of protein structure stability as a major causative factor in monogenic disease P Yue, Z Li, J Moult Journal of molecular biology 353 (2), 459-473, 2005 | 550 | 2005 |
| Androgen Deprivation Causes Epithelial-Mesenchymal Transition in the Prostate: Implications for Androgen-deprivation Therapy Y Sun, BE Wang, KG Leong, P Yue, L Li, S Jhunjhunwala, D Chen, K Seo, ... Cancer Research, 2011 | 401 | 2011 |
| Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation BS Jaiswal, V Janakiraman, NM Kljavin, S Chaudhuri, HM Stern, W Wang, ... Cancer cell 16 (6), 463-474, 2009 | 337 | 2009 |
| TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer S Stinson, MR Lackner, AT Adai, N Yu, HJ Kim, C O’Brien, J Spoerke, ... Science signaling 4 (177), ra41-ra41, 2011 | 327 | 2011 |
| The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation D Raha, TR Wilson, J Peng, D Peterson, P Yue, M Evangelista, C Wilson, ... Cancer research 74 (13), 3579-3590, 2014 | 318 | 2014 |
| Identification and analysis of deleterious human SNPs P Yue, J Moult Journal of molecular biology 356 (5), 1263-1274, 2006 | 307 | 2006 |
| Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma D Dornan, F Bennett, Y Chen, M Dennis, D Eaton, K Elkins, D French, ... Blood, The Journal of the American Society of Hematology 114 (13), 2721-2729, 2009 | 296 | 2009 |
| Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models EA Punnoose, JD Leverson, F Peale, ER Boghaert, LD Belmont, N Tan, ... Molecular cancer therapeutics 15 (5), 1132-1144, 2016 | 294 | 2016 |
| Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B S Menne, DB Tumas, KH Liu, L Thampi, D AlDeghaither, BH Baldwin, ... Journal of hepatology 62 (6), 1237-1245, 2015 | 232 | 2015 |
| Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells D Mérino, SL Khaw, SP Glaser, DJ Anderson, LD Belmont, C Wong, ... Blood, The Journal of the American Society of Hematology 119 (24), 5807-5816, 2012 | 224 | 2012 |
| miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer S Stinson, MR Lackner, AT Adai, N Yu, HJ Kim, C O’Brien, J Spoerke, ... Science signaling 4 (186), pt5-pt5, 2011 | 181 | 2011 |
| miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer MS Hwang, N Yu, SY Stinson, P Yue, RJ Newman, BB Allan, D Dornan PloS one 8 (6), e66502, 2013 | 169 | 2013 |
| Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models M Wong, N Tan, J Zha, FV Peale, P Yue, WJ Fairbrother, LD Belmont Molecular cancer therapeutics 11 (4), 1026-1035, 2012 | 120 | 2012 |
| Navitoclax enhances the efficacy of taxanes in non–small cell lung cancer models N Tan, M Malek, J Zha, P Yue, R Kassees, L Berry, WJ Fairbrother, ... Clinical Cancer Research 17 (6), 1394-1404, 2011 | 100 | 2011 |
| Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models N Tan, M Wong, MA Nannini, R Hong, LB Lee, S Price, K Williams, ... Molecular cancer therapeutics 12 (6), 853-864, 2013 | 83 | 2013 |
| MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors V Juric, C O'Sullivan, E Stefanutti, M Kovalenko, A Greenstein, ... PLoS One 13 (11), e0207255, 2018 | 79 | 2018 |
